Literature DB >> 22894935

Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase.

Kadin Karakaya1, Friederike Herbst, Claudia Ball, Hanno Glimm, Alwin Krämer, Harald Löffler.   

Abstract

Ectopic viral integration site 1 (EVI1), a transcription factor frequently overexpressed in myeloid neoplasias, has been implicated in the generation of malignancy-associated centrosomal aberrations and chromosomal instability. Here, we sought to investigate the underlying cause of centrosome amplification in EVI1-overexpressing cells. We found that overexpression of EVI1-HA in U2OS cells induced supernumerary centrosomes, which were consistently associated with enlarged nuclei or binuclear cells. Live cell imaging experiments identified cytokinesis failure as the underlying cause of this phenotype. In accordance with previous reports, EVI1 overexpression induced a partial cell cycle arrest in G0/1 phase, accompanied by elevated cyclin D1 and p21 levels, reduced Cdk2 activity and activation of the p53 pathway. Supernumerary centrosomes predominantly occurred in resting cells, as identified by low levels of the proliferation marker Ki-67, leading to the conclusion that they result from tetraploidization after cytokinesis failure and are confined to G0/1-arrested tetraploid cells. Depletion of p53 using siRNA revealed that further polyploidization of these cells was inhibited by the p53-dependent tetraploidy checkpoint.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22894935      PMCID: PMC3467026          DOI: 10.4161/cc.21801

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  53 in total

1.  Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia.

Authors:  S Ogawa; M Kurokawa; T Tanaka; K Tanaka; A Hangaishi; K Mitani; N Kamada; Y Yazaki; H Hirai
Journal:  Leukemia       Date:  1996-05       Impact factor: 11.528

2.  Chromosomal abnormality inv(3)(q21q26) associated with multilineage hematopoietic progenitor cells in hematopoietic malignancies.

Authors:  G Shi; H J Weh; U Dührsen; W Zeller; D K Hossfeld
Journal:  Cancer Genet Cytogenet       Date:  1997-07-01

3.  Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study.

Authors:  L M Secker-Walker; A Mehta; B Bain
Journal:  Br J Haematol       Date:  1995-10       Impact factor: 6.998

4.  SAS-6 defines a protein family required for centrosome duplication in C. elegans and in human cells.

Authors:  Sebastian Leidel; Marie Delattre; Lorenzo Cerutti; Karine Baumer; Pierre Gönczy
Journal:  Nat Cell Biol       Date:  2005-02       Impact factor: 28.824

5.  Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts.

Authors:  A Kilbey; V Stephens; C Bartholomew
Journal:  Cell Growth Differ       Date:  1999-09

Review 6.  Genetic instabilities in human cancers.

Authors:  C Lengauer; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

7.  Expression of the Evi-1 gene in myelodysplastic syndromes.

Authors:  F Dreyfus; D Bouscary; J Melle; V Ribrag; M Guesnu; B Varet
Journal:  Leukemia       Date:  1995-01       Impact factor: 11.528

8.  Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.

Authors:  J H Ohyashiki; K Ohyashiki; T Shimamoto; K Kawakubo; T Fujimura; S Nakazawa; K Toyama
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

Review 9.  Aneuploidy and cancer.

Authors:  Harith Rajagopalan; Christoph Lengauer
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

10.  Expression of the zinc finger gene EVI-1 in ovarian and other cancers.

Authors:  D J Brooks; S Woodward; F H Thompson; B Dos Santos; M Russell; J M Yang; X Y Guan; J Trent; D S Alberts; R Taetle
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

View more
  10 in total

1.  Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.

Authors:  A Sayadi; J Jeyakani; S H Seet; C-L Wei; G Bourque; F A Bard; N A Jenkins; N G Copeland; E A Bard-Chapeau
Journal:  Oncogene       Date:  2015-08-03       Impact factor: 9.867

2.  Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia.

Authors:  Beate Vajen; Kathrin Thomay; Brigitte Schlegelberger
Journal:  Cancers (Basel)       Date:  2013-07-04       Impact factor: 6.639

3.  EVI1 promotes tumor growth via transcriptional repression of MS4A3.

Authors:  Gerwin Heller; Anna Rommer; Katarina Steinleitner; Julia Etzler; Hubert Hackl; Petra Heffeter; Erwin Tomasich; Martin Filipits; Birgit Steinmetz; Thais Topakian; Simone Klingenbrunner; Barbara Ziegler; Andreas Spittler; Sabine Zöchbauer-Müller; Walter Berger; Rotraud Wieser
Journal:  J Hematol Oncol       Date:  2015-03-21       Impact factor: 17.388

4.  Cytokinesis arrest and multiple centrosomes in B cell chronic lymphocytic leukaemia.

Authors:  Marie Rogne; Oksana Svaerd; Julia Madsen-Østerbye; Adnan Hashim; Geir E Tjønnfjord; Judith Staerk
Journal:  J Cell Mol Med       Date:  2018-03-07       Impact factor: 5.310

5.  MECOM/PRDM3 and PRDM16 Serve as Prognostic-Related Biomarkers and Are Correlated With Immune Cell Infiltration in Lung Adenocarcinoma.

Authors:  Meng Li; Hui Ren; Yanpeng Zhang; Na Liu; Meng Fan; Ke Wang; Tian Yang; Mingwei Chen; Puyu Shi
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

6.  EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages.

Authors:  Katarina Steinleitner; Paulina Rampetsreiter; Rene Köffel; Gajalakshmi Ramanathan; Christine Mannhalter; Herbert Strobl; Rotraud Wieser
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

7.  New functions for ecotropic viral integration site 1 (EVI1), an oncogene causing aggressive malignant disease.

Authors:  Rotraud Wieser
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

8.  EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.

Authors:  Anna Rommer; Birgit Steinmetz; Friederike Herbst; Hubert Hackl; Petra Heffeter; Daniela Heilos; Martin Filipits; Katarina Steinleitner; Shayda Hemmati; Irene Herbacek; Ilse Schwarzinger; Katharina Hartl; Pieter Rondou; Hanno Glimm; Kadin Karakaya; Alwin Krämer; Walter Berger; Rotraud Wieser
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

9.  The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.

Authors:  Birgit Steinmetz; Hubert Hackl; Eva Slabáková; Ilse Schwarzinger; Monika Smějová; Andreas Spittler; Itziar Arbesu; Medhat Shehata; Karel Souček; Rotraud Wieser
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 10.  Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies.

Authors:  Karuna Mittal; Jaspreet Kaur; Meghan Jaczko; Guanhao Wei; Michael S Toss; Emad A Rakha; Emiel Adrianus Maria Janssen; Håvard Søiland; Omer Kucuk; Michelle Dian Reid; Meenakshi V Gupta; Ritu Aneja
Journal:  Cancer Metastasis Rev       Date:  2020-10-26       Impact factor: 9.264

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.